These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2133274)

  • 1. Human prostacyclin platelet receptors and platelet lipid composition.
    Modesti PA; Abbate R; Prisco D; Gensini GF
    J Lipid Mediat; 1990; 2(6):309-15. PubMed ID: 2133274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of selective [3H]iloprost binding sites on human platelet membranes.
    Steurer G; Jankovic B; Ettl K; Schernthaner G
    Prog Clin Biol Res; 1987; 242():25-34. PubMed ID: 2444987
    [No Abstract]   [Full Text] [Related]  

  • 3. Human prostacyclin platelet receptors in diabetes mellitus.
    Modesti PA; Fortini A; Gensini GF; Vanni D; Prisco D; Abbate R
    Thromb Res; 1991 Sep; 63(5):541-8. PubMed ID: 1755006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets.
    Kajikawa N; Nogimori K; Murata T; Nishio S; Uchiyama S
    Arzneimittelforschung; 1989 Apr; 39(4):495-9. PubMed ID: 2665758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
    Schrör K; Löbel P; Steinhagen-Thiessen E
    Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of platelet [3H] iloprost binding by cholesterol, dibucaine and pentoxifylline.
    Jaschonek K; Funck M; Muller CP; Schmidt H
    Prog Clin Biol Res; 1989; 301():321-5. PubMed ID: 2477853
    [No Abstract]   [Full Text] [Related]  

  • 7. Age related changes of platelet prostacyclin receptors in humans.
    Modesti PA; Fortini A; Abbate R; Gensini GF
    Eur J Clin Invest; 1985 Aug; 15(4):204-8. PubMed ID: 2995049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes.
    Lombroso M; Nicosia S; Paoletti R; Whittle BJ; Moncada S; Vane JR
    Prostaglandins; 1984 Feb; 27(2):321-33. PubMed ID: 6326201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The platelet rebound phenomenon during PGI2-infusion occurs at the receptor level.
    Steurer G; Fitscha P; Sinzinger H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):435-8. PubMed ID: 2465947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in prostacyclin platelet receptors in active spontaneous angina.
    Neri Serneri GG; Modesti PA; Fortini A; Abbate R; Lombardi A; Gensini GF
    Lancet; 1984 Oct; 2(8407):838-41. PubMed ID: 6148573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Ex vivo" influence of fatty acids from plasma cholesterol and triglycerides on the fatty acid pattern of platelets.
    Aznar J; Santos T; Vallés J
    Thromb Haemost; 1985 Oct; 54(3):669-74. PubMed ID: 4089796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Separate receptors for prostacyclin and prostaglandin E2 on human gel-filtered platelets.
    Eggerman TL; Andersen NH; Robertson RP
    J Pharmacol Exp Ther; 1986 Mar; 236(3):568-73. PubMed ID: 2869139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets.
    Fortini A; Modesti PA; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Res; 1985 Nov; 40(3):319-28. PubMed ID: 3001968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (5Z)-carbacyclin displays agonist-antagonist properties on prostacyclin-receptors in platelets and vascular myocytes.
    Corsini A; Oliva D; Folco GC; Giovanazzi S; Noe' MA; Fumagalli R; Nicosia S
    Biomed Biochim Acta; 1988; 47(10-11):S104-7. PubMed ID: 3073757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of changes in the lipid composition of membranes on the functional activity of platelets].
    Ishankhodzhaev TM; Bornikov VT; Zaĭnutdinov BR; Saatov TS
    Biokhimiia; 1990 Aug; 55(8):1507-12. PubMed ID: 2288990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombocyte prostacyclin receptors in gestational hypertension and pre-eclampsia].
    Klockenbusch W; Hohlfeld T; Hafner D; Wilhelm M; Somville T; Schrör K
    Z Geburtshilfe Neonatol; 1996; 200(3):96-9. PubMed ID: 8963891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol:phospholipid ratio is elevated in platelet plasma membrane in patients with hypertension.
    Benjamin N; Robinson BF; Graham JG; Wilson RB
    J Hum Hypertens; 1990 Jun; 4(3):273-6. PubMed ID: 2362260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solubilization of prostacyclin membrane receptors from human platelets.
    Tsai AL; Hsu MJ; Vijjeswarapu H; Wu KK
    J Biol Chem; 1989 Jan; 264(1):61-7. PubMed ID: 2642482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
    Tahraoui L; Floch A; Cavero I
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiaggregatory effectiveness of PGI2 and its binding to specific platelet receptors. A comparative study.
    Jaschonek K; Renn W; Weisenberger H
    Prog Clin Biol Res; 1987; 242():13-8. PubMed ID: 3313410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.